Jansen E N
Eur Neurol. 1978;17(2):92-9. doi: 10.1159/000114930.
23 patients with advanced Parkinson's disease were allocated in a double-blind study of bromocryptine. These patients had an insufficient or deteriorating response to levodopa treatment. The dosages of levodopa were optimal and stabilized 3 months prior to and during this 5-month study. The addition of bromocryptine in high doses (average daily dose 71 mg) induced a significant improvement in the total score of the Webster and the NUDS scales. The global assessment, both by the investigator and by the patients, also showed significant improvement. The efficacy of bromocryptine in these type of parkinsonian patients in a double-blind trial has not yet been established. The conclusion of this trial is that bromocryptine significantly increases the therapeutic effectiveness in these poorly levodopa responding parkinsonian patients.
23例晚期帕金森病患者被纳入一项关于溴隐亭的双盲研究。这些患者对左旋多巴治疗反应不足或病情恶化。在这项为期5个月的研究之前及期间，左旋多巴的剂量均已达到最佳且稳定状态，为期3个月。添加高剂量溴隐亭（平均每日剂量71毫克）后，韦伯斯特量表和纽卡斯尔大学多巴胺能症状量表的总分显著改善。研究者和患者的整体评估也显示出显著改善。溴隐亭在这类帕金森病患者双盲试验中的疗效尚未确立。该试验的结论是，溴隐亭可显著提高这些对左旋多巴反应不佳的帕金森病患者的治疗效果。
